SCHEDULE 13D/A: Pfizer Updates Haleon Stake Disclosure, Director Departs Following Relationship Agreement Termination

Pfizer Inc. filed an Amendment No. 13 to its Schedule 13D, disclosing its continued beneficial ownership of 7.3% of Haleon plc's Ordinary Shares and the departure of its nominated director, Mr. Supran, following the termination of the Pfizer Relationship Agreement.

Summary

• Pfizer Inc. filed Amendment No. 13 to its Schedule 13D regarding its beneficial ownership in Haleon plc.
• As of February 25, 2025, Pfizer beneficially owns 661,709,764 Ordinary Shares of Haleon plc.
• This represents approximately 7.3% of Haleon's outstanding Ordinary Shares, calculated based on 9,054,145,714 shares outstanding as of January 31, 2025, as reported by Haleon on its Form 6-K.
• On February 25, 2025, Pfizer withdrew Ordinary Shares previously held under a restricted American Depositary Receipts facility; this action did not change the total number of shares beneficially owned.
• Mr. Supran stepped down from Haleon's Board of Directors on February 25, 2025, as the Pfizer Relationship Agreement terminated after the January 2025 Secondary Offering, removing Pfizer's contractual right to nominate directors.

Sentiment

Score: 5

Explanation: The document is neutral, primarily reporting a procedural change in shareholding and an expected corporate governance adjustment following a pre-arranged agreement termination. It does not contain new positive or negative financial performance information.

Positives

• The number of Ordinary Shares beneficially owned by Pfizer remains unchanged despite the procedural withdrawal from the American Depositary Receipts facility, indicating stable direct ownership.

Negatives

• The termination of the Pfizer Relationship Agreement means Pfizer no longer has the contractual right to nominate directors to Haleon's Board, reducing its direct influence on corporate governance.

Risks

• Reduced influence of Pfizer on Haleon's corporate governance due to the termination of the Pfizer Relationship Agreement and the stepping down of its nominated director.

Future Outlook

The document does not contain explicit forward-looking statements or guidance beyond the immediate effects of the relationship agreement termination and share withdrawal.

Industry Context

This filing reflects the ongoing unwinding of Pfizer's historical stake in Haleon, a consumer healthcare company spun off from GSK. The reduction in Pfizer's board representation is a natural progression as it divests its non-core assets and reduces its ownership, allowing Haleon to operate more independently. This is consistent with a trend of large pharmaceutical companies streamlining their portfolios.

Comparison to Industry Standards

• This document primarily concerns a change in beneficial ownership and corporate governance structure rather than financial performance. Therefore, direct comparisons to industry financial benchmarks or specific projects are not applicable.
• The reduction of a major shareholder's influence on a spun-off entity's board is a standard outcome as the parent company reduces its stake.

Management Changes

Corporate Governance

Related Party Transactions

• Termination of Pfizer Relationship Agreement following the January 2025 Secondary Offering, which previously granted Pfizer the right to nominate directors.

Stakeholder Impact

• Shareholders: Pfizer's continued 7.3% stake provides some stability, but the reduced board representation means less direct oversight from a major founding shareholder. This could be seen as a move towards greater independence for Haleon.
• Management/Board: The board composition changes with the departure of a Pfizer-nominated director, potentially shifting internal dynamics and strategic direction.

Key Dates

Recommendation

Keywords

Haleon plc, Pfizer Inc., Schedule 13D, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Corporate Governance, Director Resignation, Shareholding, SEC Filing, Consumer Healthcare